Tela Bio, Inc. (TELA) intrinsic value & 10-year financials
Tela Bio, Inc. (TELA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 44.4% a year to $80.3M, with an average return on invested capital of -230.3%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.98
- Market cap
- $45.8M
- Revenue (FY2025)
- $80.3M
- Revenue growth (10-yr CAGR)
- 44.4%
- ROIC (10-yr avg)
- -230.3%
- Free cash flow (FY2025)
- -$28.7M
TELA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $80.3M | -$38.8M | -$0.83 | -$28.7M | -42.0% | -229.4% |
| FY2024 | $69.3M | -$37.8M | -$1.33 | -$42.6M | -49.2% | -208.0% |
| FY2023 | $58.5M | -$46.7M | -$2.04 | -$41.5M | -75.4% | -336.1% |
| FY2022 | $41.4M | -$44.3M | -$2.72 | -$41.6M | -94.2% | -420.7% |
| FY2021 | $29.5M | -$33.3M | -$2.30 | -$31.1M | -100.0% | -507.4% |
| FY2020 | $18.2M | -$28.8M | -$2.23 | -$24.6M | -138.8% | -269.6% |
| FY2019 | $15.4M | -$22.4M | -$2.44 | -$25.7M | -124.1% | -141.0% |
| FY2018 | $8.3M | -$21.1M | — | -$20.0M | -214.9% | 17.1% |
| FY2017 | $4.2M | -$21.3M | — | -$16.5M | -398.7% | 22.5% |
| FY2016 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
TELA Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
TELA Bio, Inc. has historically struggled to out-earn its cost of capital, averaging just -13.4% ROIC.
TELA Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, TELA Bio, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-27.57 per share.